Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension

Shock

Volumn 28, Issue 4, 2007, Pages 468-476

  Gupta, Akanksha ^a   Berg, David T ^a   Gerlitz, Bruce ^a   Richardson, Mark A ^a   Galbreath, Elizabeth ^a   Syed, Samreen ^a   Sharma, Avadhesh C ^b   Lowry, Stephen F ^c   Grinnell, Brian W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Activated protein C; Adrenomedullin; Endothelial cells; Hypotension; IFN ; iNOS

Indexed keywords

ACTIVATED PROTEIN C; ADRENOMEDULLIN; DROTRECOGIN; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTOXEMIA; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ADRENOMEDULLIN; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; HYPOTENSION; INTERFERON TYPE II; LEUKOCYTES; LIPOPOLYSACCHARIDES; LUNG; MALE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; NITROGEN OXIDES; PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34548671607     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3180487f09     Document Type: Article

References (48)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
3. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064, 1992.
4. Szabo C, Mitchell JA, Thiemermann C, Vane JR: Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108:786-792, 1993.
5. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
6. O'Brien LA, Gupta A, Grinnell BW: Activated protein C and sepsis. Front Biosci 11:676-698, 2006.
7. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 32:1011-1017, 2004.
8. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34:1918-1924, 2006.
9. Mizutani A, Okajima K, Uchiba M, Noguchi T: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 95:3781-3787, 2000.
10. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87:642-647, 1996.
11. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
12. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834-840, 2003.
13. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21:222-229, 2004.
14. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matuschak GM, Salvemini D: A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin induced shock. J Pharmacol Exp Ther 319:73-81, 2006.
15. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M: Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 28:1631-1639, 1996.
16. Schletter J, Heine H, Ulmer AJ, Rietschel ET: Molecular mechanisms of endotoxin activity. Arch Microbiol 164:383-389, 1995.
17. Olsson LE, Wheeler MA, Sessa WC, Weiss RM: Bladder instillation and intraperitoneal injection of Escherichia coli lipopolysaccharide up-regulate cytokines and iNOS in rat urinary bladder. J Pharmacol Exp Ther 284:1203-1208, 1998.
18. Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84:903-934, 2004.
19. Isumi Y, Shoji H, Sugo S, Tochimoto T, Yoshioka M, Kangawa K, Matsuo H, Minamino N: Regulation of adrenomedullin production in rat endothelial cells. Endocrinology 139:838-846, 1998.
20. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H: Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 207:25-32, 1995.
21. Wang P: Adrenomedullin in sepsis and septic shock. Shock 10:383-384, 1998.
22. Titheradge MA: Nitric oxide in septic shock. Biochim Biophys Acta 1411:437-455, 1999.
23. Nishio K, Akai Y, Murao Y, Doi N, Ueda S, Tabuse H, Miyamoto S, Dohi K, Minamino N, Shoji H, et al.: Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 25:953-957, 1997.
24. Gupta A, Sharma AC: Metalloendopeptidase inhibition regulates phosphorylation of p38-mitogen-activated protein kinase and nitric oxide synthase in heart after endotoxemia. Shock 20:375-381, 2003.
25. Zhang H, Teng X, Snead C, Catravas JD: Non-NF-kappaB elements are required for full induction of the rat type II nitric oxide synthase in vascular smooth muscle cells. Br J Pharmacol 130:270-278, 2000.
26. Franscini N, Bachli EB, Blau N, Leikauf MS, Schaffner A, Schoedon G: Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 110:2903-2909, 2004.
27. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9:338-342, 2003.
28. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296:1880-1882, 2002.
29. Dotsch J, Schoof E, Hanze J, Dittrich K, Opherk P, Dumke K, Rascher W: Nitric oxide stimulates adrenomedullin secretion and gene expression in endothelial cells. Pharmacology 64:135-139, 2002.
30. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K: Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104:1171-1175, 2001.
31. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471-1477, 1993.
32. Landry DW, Oliver JA: The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992.
33. Wang P, Zhou M, Ba ZF, Cioffi WG, Chaudry IH: Up-regulation of a novel potent vasodilatory peptide adrenomedullin during polymicrobial sepsis. Shock 10:118-122, 1998.
34. Hofbauer KH, Schoof E, Kurtz A, Sandner P: Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathways. Hypertension 39:161-167, 2002.
35. Ornan DA, Chaudry IH, Wang P: Pulmonary clearance of adrenomedullin is reduced during the late stage of sepsis. Biochim Biophys Acta 1427:315-321, 1999.
36. Shindo T, Kurihara H, Maemura K, Kurihara Y, Kuwaki T, Izumida T, Minamino N, Ju KH, Morita H, Oh-hashi Y, et al.: Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation 101:2309-2316, 2000.
37. Majid DS, Kadowitz PJ, Coy DH, Navar LG: Renal responses to intra-arterial administration of adrenomedullin in dogs. Am J Physiol 270:F200-F205, 1996.
38. Feng CJ, Kang B, Kaye AD, Kadowitz PJ, Nossaman BD: L-NAME modulates responses to adrenomedullin in the hindquarters vascular bed of the rat. Life Sci 55:L433-L438, 1994.
39. Nossaman BD, Feng CJ, Kaye AD, DeWitt B, Coy DH, Murphy WA, Kadowitz PJ: Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol 270:L782-L789, 1996.
40. De Matteo R, May CN: Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. Br J Pharmacol 140:1414-1420, 2003.
41. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr: Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92:286-289, 1995.
42. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, Hanada Y, Nagatomo Y, Takenaga M, Ishikawa T, et al.: Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 131:676-680, 1996.
43. Shoji H, Minamino N, Kangawa K, Matsuo H: Endotoxin markedly elevates plasma concentration and gene transcription of adrenomedullin in rat. Biochem Biophys Res Commun 215:531-537, 1995.
44. Yang S, Zhou M, Chaudry IH, Wang P: The role of lipopolysaccharide in stimulating adrenomedullin production during polymicrobial sepsis. Biochim Biophys Acta 1537:167-174, 2001.
45. Shimekake Y, Nagata K, Ohta S, Kambayashi Y, Teraoka H, Kitamura K, Eto T, Kangawa K, Matsuo H: Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. J Biol Chem 270:4412-4417, 1995.
46. Grinnell BW, Joyce D: Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29:53-60, 2001. [discussion S60-S61].
47. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:11199-11203, 2001.
48. Joyce DE, Nelson DR, Grinnell BW: Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med 32:280-286, 2004.